Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma

Autor:	Ronald J. Schmitt, Brian M. Bagrosky, Jennifer J. Kwak, Karl D. Lewis, Sarah M. Kreidler, Rodabe N. Amaria, Rene Gonzalez, Deborah H. Glueck, Phillip J. Koo
Rok vydání:	2016
Předmět:	Oncology medicine.medical_specialty 030218 nuclear medicine & medical imaging 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Internal medicine medicine Radiology Nuclear Medicine and imaging Vemurafenib neoplasms Trametinib Fluorodeoxyglucose Cobimetinib PET-CT medicine.diagnostic_test business.industry Melanoma Dabrafenib General Medicine medicine.disease carbohydrates (lipids) chemistry Positron emission tomography 030220 oncology & carcinogenesis business medicine.drug
Zdroj:	Nuclear Medicine Communications. 37:122-128
ISSN:	0143-3636
Popis:	PurposeMetabolic response to treatment measured by fluorine-18 fluorodeoxyglucose (18F-FDG) PET has prognostic implications in many cancers. This study investigated the association between survival and early changes on 18F-FDG PET/computed tomography (CT) for patients with BRAF-mutant melanoma recei
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::260048471f129f781784d5265b6909cc https://doi.org/10.1097/mnm.0000000000000406 Zobrazit plný text záznamu